Baptist Health South Florida ‘Saved by the Scan’ Campaign Increases Lifesaving Screenings

Today, Baptist Health South Florida and the American Lung Association announced they will extend their partnership to raise awareness for lung cancer screenings through the proven and successful “Saved by the Scan” campaign. This partnership was created in 2021 and is the first of its kind bringing together a large healthcare organization and the American Lung Association.

While cancer screenings during the pandemic declined nationally, lung cancer screenings at Baptist Health South Florida facilities over the past year have increased, according to campaign data gathered by Baptist Health South Florida. The low-dose CT scan lung cancer screening can detect lung cancer in the early stages, before symptoms arise, when the disease is more curable. In just one year, this campaign has made a lifesaving impact at Baptist Health with a 62% increase year-over-year of lung cancer screenings and a 29% increase over pre-COVID numbers.

“The significant increase of lung cancer screenings at Baptist Health is a true testament to the demonstrated commitment made by Baptist Health and the Lung Association,” Dr. Mark J. Hauser, chair of the South Florida Local Leadership Board for the American Lung Association, pulmonologist and president of medical staff affairs for Baptist Health. “While this partnership continues to evolve and the results have exceeded our expectations, there is still so much more work to be done to shine a light on the value of early lung cancer screenings.”

“Many people aren’t aware that with a quick, painless and safe test, they can be screened for lung cancer,” said Manmeet Ahluwalia, M.C., deputy director, chief scientific officer and chief of solid tumor medical oncology at Baptist Health’s Miami Cancer Institute. “We are glad that more people at risk are taking advantage of this test.”

According to the American Lung Association, lung cancer is the leading cancer killer. The “Saved by the Scan” campaign is a public service advertising program aimed at educating Americans about the groundbreaking lung cancer screening for those at high risk for the disease.

In 2014, Mark Dylewski, M.D., chief of general thoracic surgery at Baptist Health, and Juan Batlle, M.D., chief of thoracic imaging at Baptist Health, spearheaded Baptist Health’s lung cancer screening program with the generous support of a grateful patient and lung cancer survivor, Dennis Bookshester.

“In the past, 60 to 70% of lung cancer patients weren’t diagnosed until the cancer was advanced,” Dr. Dylewski said. “With the implementation of screenings, we are catching more patients in the earlier stages where surgery can have a bigger impact. If lung cancer is caught before it spreads, the chance of surviving five years or more increases to over 60%.”

The campaign targets the millions of people who are at high risk for lung cancer and should talk to their doctor about getting a low-dose CT scan lung cancer screening. A person is considered high risk for lung cancer if they are between 50–80 years old, have a 20-pack year history of smoking (this means 1 pack a day for 20 years, 2 packs a day for 10 years, etc.), and are a current smoker, or have quit within the last 15 years.

“In Florida, it is estimated that 19,560 people will be diagnosed with lung cancer and 10,440 will succumb to the disease in 2022. Lung cancer screening is the only way to detect the disease at an early stage when it is more curable,” said Chrissy Cohen, executive director for the Lung Association in South Florida. “Unfortunately, only 3.4% of people in Florida who qualify have had a lung cancer screening. This is why this partnership is critical to raise awareness about this lifesaving screening.”

The screening is available throughout Baptist Health. For eligible patients, Medicare and most private insurance companies cover the screening cost so it is free to the patient.

The South Florida “Saved by the Scan” comprehensive public awareness campaign includes a video public service announcement, digital and print advertisements, and social media. For more information about the campaign, visit BaptistHealth.net/LungScreening.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version